Panelists discuss how cytoreductive therapy fits into the treatment paradigm for polycythemia vera (PV), highlighting key findings from the CYTO-PV study and its subanalysis, which inform their treatment decisions for patients with PV.
Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.
SHR-1701 plus CAPOX chemotherapy elicited fewer chemo delays and dose reductions and improved AE data vs placebo plus CAPOX in HER2-negative gastric/GEJ cancer.
Evorpacept plus TRP produced superior ORR, DOR, and PFS outcomes vs TRP alone in patients with HER2-positive gastric or gastroesophageal junction cancer.
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
Panelists discuss how myelofibrosis can evolve following initial treatment, examining common patterns of disease progression and strategies for adapting therapeutic approaches based on individual patient…
In this issue of Cancer Cell, Ellrott et al. present machine learning models to classify samples into The Cancer Genome Atlas (TCGA) molecular subtypes using compact…
An abstract is unavailable.
An abstract is unavailable.
Rene Y. McNall-Knapp, MD, discusses HRQOL outcomes from the ReNeu trial investigating mirdametinib in patients with NF1-PN.
IASLC presents a one-hour, live session focused on key highlights from the 2024 Hot Topic in Basic & Translational Science Conference. This webinar will…
